Physician profile
David E Allie
NPI 1760489728
$666,474.53
in general payments reported to CMS, 2019-2025
28 companies · $7,377 in 2025
The $7,377 reported for 2025 was more than what 87% of Thoracic Surgery (Cardiothoracic Vascular Surgery) providers received nationally (typical 2025 total: $796).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $128K · 2020: $161K · 2021: $356K · 2022: $2,026 · 2023: $7,819 · 2024: $3,258 · 2025: $7,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $8,389 · Debt Forgiveness: $7,200 · Acquisitions: $1,665 · Food and Beverage: $1,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $8,389.34 |
| Debt Forgiveness | $7,200.00 |
| Acquisitions | $1,665.44 |
| Food and Beverage | $1,198.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $301,454.55 | 2019-2025 | Venclose Maven Catheter |
| Anika Therapeutics, INC. | $191,532.99 | 2020-2021 | |
| Cardiovascular Systems INC. | $68,229.92 | 2019-2020 | |
| Catheter Precision, INC. Fka Ra Medical Systems, INC. | $57,125.00 | 2019 | |
| Angiodynamics, INC. | $17,839.57 | 2020-2025 | Auryon Laser System 100-120 Vac, Venacure 1470 Pro, Auryon Laser System 100-120 Vac |
| Philips North America LLC | $13,917.00 | 2019-2020 | |
| Convatec INC. | $7,222.21 | 2023-2025 | |
| Biotronik INC. | $5,120.18 | 2019 | |
| Idev Technologies, INC. | $1,814.38 | 2020 | |
| Abbott Laboratories | $693.25 | 2019 | |
| Boston Scientific Corporation | $365.22 | 2019-2025 | Bodyguardian |
| Janssen Pharmaceuticals, INC | $279.31 | 2019-2022 | |
| Veryan Medical Incorporated | $275.81 | 2021 | |
| Medtronic Vascular, INC. | $159.82 | 2020 | |
| Pfizer INC. | $95.11 | 2020-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $54.41 | 2020-2021 | |
| Cardiva Medical, INC. | $48.45 | 2021 | |
| Smith+Nephew, INC. | $46.32 | 2019-2021 | |
| Medtronic, INC. | $40.22 | 2021-2022 | |
| Silk Road Medical, INC. | $37.47 | 2021 | |
| Becton, Dickinson and Company | $32.65 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $28.72 | 2025 | Exparel, Iovera |
| Tactile Systems Technology INC | $22.48 | 2019 | |
| Kerecis Limited | $15.41 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Amgen INC. | $14.97 | 2024 | Repatha |
| Musculoskeletal Transplant Foundation INC. | $9.11 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$4,999.99 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$499,200.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Allie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.